Media & Investor Relations:
Troy Wichterman
Chief Financial Officer
(425) 402 - 1400
twichterman@biolifesolutions.com
Broadridge Corporate Issuer Solutions, Inc.
P.O. Box 1342
Brentwood, New York 11717
USA
(877) 830 - 4936
shareholder@broadridge.com
Register here to receive email notifications with updates about our press releases, stock price, SEC filings and more.
Press Releases
These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email link below.
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
- Aug 08 2024
Cell Processing revenue increased 11% sequentially to $18.0 million GAAP gross margin of 51% and non-GAAP adjusted gross margin of 52% GAAP net loss from continuing operations of $7.1 million and...
- Jul 25 2024
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced...
- May 29 2024
New container developed for the needs of cell and gene therapy (CGT) primary packaging to replace cryopreservation bags with a fracture resistant, rigid construction built for both manual use and...
- May 09 2024
Cell Processing revenue increased 10% sequentially to $16.2 million GAAP gross margin of 38% and net loss of $10.2 million Non-GAAP adjusted gross margin expands from 40% to 53% and adjusted EBITDA of
- Apr 30 2024
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced...